Brinks CompanyBrink's proposes divesting its NoteMachine/TestLink UK business to clear the CMA review of its NCR Atleos acquisition, keeping the deal on track.
The Brink's Company said it has agreed to propose the divestiture of its NoteMachine/TestLink UK business in connection with the United Kingdom's Competition and Markets Authority review of its planned acquisition of NCR Atleos Corporation. The company said the CMA's Phase 1 decision reflects the local overlap between Brink's NoteMachine/TestLink UK business and NCR Atleos' Cardtronics business in the UK, and that the decision came under the CMA's fast-track Phase 1 procedure following constructive engagement. Brink's said the potential sale of NoteMachine/TestLink UK was a remedy contemplated in the financial metrics it has previously disclosed and does not impact the $200 million in annual run-rate cost synergies it still expects to achieve within three years of closing the transaction. The proposed sale process is progressing, with a number of prospective buyers having expressed strong preliminary interest, the company said. Brink's said the NCR Atleos acquisition remains on track to close early in the first quarter of 2027.
Brinks CompanyBrink's proposes divesting its NoteMachine/TestLink UK business to clear the CMA review of its NCR Atleos acquisition, keeping the deal on track.
NCR Atleos CorporationThe CMA remedy clears a regulatory hurdle for Brink's planned acquisition of NCR Atleos, keeping the deal on track to close in Q1 2027.
NoteMachine/TestLink UK is the Brink's unit being proposed for divestiture to resolve the CMA overlap, but no standalone impact is stated.
Cardtronics is mentioned only as the NCR Atleos UK business overlapping with Brink's NoteMachine/TestLink, the source of the CMA concern.